WO2026109043 - MGAT2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/109043
Publication Date
28.05.2026
International Application No.
PCT/CN2025/137295
International Filing Date
25.11.2025
Title **
[English]
MGAT2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
[French]
INHIBITEUR DE MGAT2, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
[Chinese]
MGAT2抑制剂及其制备方法和用途
Applicants **
CHENGDU CHIPSCREEN PHARMACEUTICAL LTD.
Inventors
LIU, Gang
WANG, Wei
SUN, Xiaoyang
LIU, Xiangkai
JIN, Heping
SHAN, Song
PAN, Desi
LU, Xianping
Priority Data
202411697204.5
25.11.2024
CN
202510780123.X
11.06.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1783 | |
| EPO | Filing, Examination, Granting | 12156 | |
| Japan | Filing, Examination, Granting | 1813 | |
| South Korea | Filing, Examination, Granting | 1438 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,930
Contact Us
Abstract[English]
The present invention relates to a compound as shown in formula (I), and a preparation method therefor and the use thereof. The present invention further relates to a pharmaceutical composition containing the compound as an active ingredient, and the use of the compound or pharmaceutical composition in the treatment and/or prevention of diseases associated with MGAT2 expression.[French]
La présente invention concerne un composé tel que représenté dans la formule (I), ainsi que son procédé de préparation et son utilisation. La présente invention concerne en outre une composition pharmaceutique contenant le composé en tant que principe actif, et l'utilisation du composé ou de la composition pharmaceutique dans le traitement et/ou la prévention de maladies associées à l'expression de MGAT2.[Chinese]
本发明涉及式(I)所示化合物及其制备方法和用途。本发明还涉及包含所述化合物作为活性成分的药物组合物以及所述化合物或药物组合物用于治疗和/或预防由MGAT2表达相关的疾病的用途。